# US 2018/0021453 A1 · Liposomal particles comprising biological molecules and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021453 A1
- Document ID: US20180021453A1
- Status: Published application
- Kind: A1
- Application number: 15/547,389
- Filed: 2016-01-28
- Published: 2018-01-25
- Earliest claimed: 2015-01-30
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: Joseph BAZZILL; James Jaehyun MOON; Yuchen FAN; Preety SAHDEV
- Web page: https://patentgrep.com/patent/US20180021453A1

## CPC

- A61K 47/6911: {the form being a liposome}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/0043: {Nose}
- A61K 31/722: Chitin, chitosan
- A61K 31/728: Hyaluronic acid
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are liposomal particles. In particular, provided herein are liposomal particles comprising molecules (e.g., antigens or drugs) and uses thereof (e.g., as a vaccine (e.g., intranasal vaccine) or drug delivery system). For example, in some embodiments, the present disclosure provides a composition comprising: a molecule encapsulated in a liposome comprising one or more cationic lipids and hyaluronic acid (HA). In some embodiments, the one or more lipids are DOTAP and/or DOPE. In some embodiments, the HA is thiolated. In some embodiments, the thiolated HA is conjugated to thiolated PEG.

## Claims

### Claim 1

A composition comprising:
A molecule encapsulated in a liposome comprising one or more cationic lipids and hyaluronic acid (HA).

### Claim 2 (depends on 1)

The composition of claim 1, wherein said one or more lipids are selected from the group consisting of DOTAP and DOPE.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said liposome comprises both DOTAP and DOPE.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said HA is thiolated.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said thiolated HA is conjugated to thiolated PEG.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said HA is present at a concentration of between 1 and 1000 μg HA per 1 mg of lipids.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said liposome further comprises an adjuvant and/or a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said adjuvant is monophosphoryl lipid A (MPLA).

### Claim 9 (depends on 1)

The composition of claim 1, wherein said molecule is selected from the group consisting of a protein, a peptide, a small molecule drug, an antibody, and a nucleic acid.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The composition of claim 1, wherein said molecule is an antigen.

### Claim 12

A composition, comprising:
A molecule encapsulated in a multilamellar lipid vesicle comprising covalent crosslinks between lipid bilayers, wherein at least two lipid bilayers in the multilamellar lipid vesicle are covalently crosslinked to each other by a thiolated biopolymer.

### Claim 13 (depends on 12)

The composition of claim 12, wherein said lipid bilayers are crosslinked via functionalized lipids.

### Claim 14 (depends on 12)

The composition of claim 12, wherein said one or more lipids are selected from the group consisting of DOTAP, DOPE, DOBAQ, and DOPC.

### Claim 15 (depends on 12)

The composition of claim 12, wherein said lipid is maleimide-functionalized or modified with dibenzocyclooctyne (DBCO).

### Claim 16 (depends on 12)

The composition of claim 12, wherein said thiolated biopolymer is selected from the group consisting of chitosan, polyglutamic acid, polyphosphazene, polyethyleneimine, polyalky acrylic acids (e.g. polymethylmethacrylate, poly(ethylacrylic acid), poly(propylacrylic acid), or poly(butylacrylic acid), HA, pegylated azide-modified polyethylenimine, branched polyethylenimine, and diazide.

### Claim 17 (depends on 12)

The composition of claim 12, wherein said thiolated biopolymer comprises multiple sulfhydryl moieties.

### Claim at position 18

18-20. (canceled)

### Claim 21

A method of delivering a molecule to a subject, comprising: administering a molecule encapsulated in a liposome comprising one or more cationic lipids and hyaluronic acid (HA) or a molecule encapsulated in a multilamellar lipid vesicle comprising covalent crosslinks between lipid bilayers, wherein at least two lipid bilayers in the multilamellar lipid vesicle are covalently crosslinked to each other by a thiolated biopolymer to a subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein said molecule is an antigen and said administering induces an immune response to said antigen in said subject.

### Claim 23 (depends on 23)

The method of claim 23, wherein said immune response induces immunity against a pathogen.

### Claim 24 (depends on 22)

The method of claim 22, wherein said antigen is a tumor antigen.

### Claim at position 23

25-27. (canceled)
